CN1506070A - Lead-removing health article containing stachyose - Google Patents
Lead-removing health article containing stachyose Download PDFInfo
- Publication number
- CN1506070A CN1506070A CNA021562075A CN02156207A CN1506070A CN 1506070 A CN1506070 A CN 1506070A CN A021562075 A CNA021562075 A CN A021562075A CN 02156207 A CN02156207 A CN 02156207A CN 1506070 A CN1506070 A CN 1506070A
- Authority
- CN
- China
- Prior art keywords
- lead
- stachyose
- health care
- zinc
- lactate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is one kind of lead-removing health article containing stachyose, and features that stachyose in 1.0-3.0 g, zinc lactate in 25-35 mg, ferrous lactate in 35-40 mg, vitamin B1 in 8-12 mg, vitamin C in 48-50 mg and CaCO3 in 0.8-1.0 g are compounded scientifically to produce synergistic effect of resisting lead toxicity and reducing lead absorption. Stachyose in the health article can adsorb heavy metal lead and amplify bifidobacterium as beneficial intestinal tract bacteria to promote lead excretion. The present invention has excellent prevention and treatment effect on lead toxicosis and lead toxic damage.
Description
Technical field the present invention relates to a kind of Pb excluding health care product that contains stachyose.By three kinds of elements of calcium, zinc, ferrum that needed by human body is provided, the interior lead of competitive antagonism body combines with transport protein, suppresses plumbous and is changed in the blood by intestinal.Be aided with V simultaneously
B1And V
CCan reduce plumbous the deposition in liver, brain and the sciatic nerve especially in a organized way, contained feature one stachyose, both adsorbable per os enters gastral lead, can promote intestinal beneficial bacterium one bifid bacillus fast breeding again, obviously shorten the intestinal emptying time, reach the effect of Plumbum removing.
Background technology is along with the develop rapidly of the modernization of industry and transportation, and the problem of plumbous environmental pollution is more and more serious.Lead is harmful heavy metal element, and it not only is widely used in many fields such as handicraft, chemical industry, traffic, but also is prevalent in occurring in nature.Plumbous more and more serious to the threat of human health.The nearest statistics of the U.S. shows that the whole America has 300～4,000,000 children to be subjected to the influence of Toxicity of Lead effect approximately.The research of countries in the world and China also proves that plumbous influence to children's health has become quite outstanding social problem.Plumbous harm to human body mainly shows three aspects: the firstth, and neural harm, cardinal symptom: neurasthenia's syndromes such as giddy, headache, unable, muscle joint aches, sleep disorder, hypomnesis, poor appetite; Sensational type, motor type and mixed type peripheral neuropathy that weight is different; Early stage appearance sensation and motor nerve conduction velocity slow down symptoms such as acroanesthesia.The secondth, the harm of digestive system, cardinal symptom: feel sick, abdominal distention, abdomen dull pain, diarrhoea or constipation etc.The 3rd is blood system harm, shows as blood, the uroporphyrin metabolite increases unusually; Peripheral blood stippled red blood cell, reticulocyte and many preferendums erythrocytosis; Slight low pigment normocytic anemia etc.The 4th is to influence the absorption of human body to calcium, ferrum, zinc, calcium, ferrum, zinc are the trace element of needed by human, participate in the multiple biochemical reactions of human body, plumbous absorption to these three kinds of elements all has inhibitory action, especially the inhibitory action to zinc is the most obvious, synthesizing of interior more than 200 kind of zinc-containing metal enzyme of zinc participation body and protein, nucleic acid, in close relations with children's growth promoter.Lead can make the metabolism of zinc get muddled, and causes a large amount of losses of zinc.In addition, plumbous particularly serious to child's harm, according to China's part urban survey in 1997～1999 years, 38.8% urban children is arranged above the lead poisoning standard.In this ratio, China has among the child below 3.3 hundred million 14 years old and is subjected to lead poisoning more than 100,000,000 and threatens.World Health Organization (WHO) appeals that developing country takes urgent measure, and tackles serious day by day lead contamination.Because child's metabolism and excretory function be imperfection all, plumbous meeting destroys hemopoietic system, slows down growth promoter.Central nervous system's ateliosis of child, more responsive to the toxicity of lead, therefore, plumbous even more serious to child's harm.Relevant discovering, leaded high child on average hanged down 14 fens than leaded low children intelligence.Can cause also that giddy, agitation, absent minded, many moving, learning difficulty, appetite are poor, multiple symptoms such as abdominal distention, stomachache, constipation, hypoevolutism, anemia, body constitution are weak, repeated cold, incoordination, drowsiness, fat, aggression.
If the drug main of Plumbum removing at present is with Ca-EDTA (Ca-EDTA), calcium calcium trisodium pentetate (Ca-DTPA), sodium dimercaptosuccinate (Na-DMS), zinc calcium trisodium pentetate (Zn-DTPA), quinamine acid solvay-type deleading reagents such as (QA).But these preparations all have certain side effect, and do not possess specificity, in Plumbum removing, necessary trace element in the body, as zinc, copper, manganese, ferrum etc. also along with discharge.In recent years, touch, successively developed both at home and abroad and driven lead salt, Nutrition-Beverage of Expelling Lead, driven plumbous tea etc., inquired into the influence to Toxicity of Lead such as some nutrients, trace element, but do not developed comparatively sophisticated product so far as yet at low-level lead joint.For this reason, develop be fit to take in early days, side effect is little, taking convenience, cost-effective lead-expelling product are the research emphasis of current Plumbum removing.
Summary of the invention the invention provides a kind of Pb excluding health care product that contains stachyose, by the scientific matching of calcium, zinc, ferrum, and synergism, antagonism Toxicity of Lead activity reduces Plumbum absorption.Be aided with the both adsorbable heavy metal lead of stachyose simultaneously, but fast breeding intestinal beneficial bacterium one bifid bacillus again obviously shortens the intestinal emptying time, promote Plumbum removing.To lead poisoning and toxic damages by excellent prevention and therapeutic effect.
A kind of lead-expelling product that contains stachyose of the present invention, its prescription is as follows:
Stachyose (by pure product) 1.0g～2.5g
Zinc lactate 30mg～35mg
Ferrous lactate (three water things) 36mg～40mg
V
B1???????????????????8mg～10mg，
V
C????????????????????45mg～50mg，
Caco
3?????????????????0.5mg～0.8g，
Correctives and right amount of auxiliary materials
The stachyose that the present invention is used, purity were 60%～95% (containing cottonseed sugar 3%～15%).Discover that stachyose can not only adsorb per os and enter gastral heavy metal, reduce lead and entered blood by intestinal absorption; Can suppress it and absorb again in conjunction with the lead that enters intestinal through bile secretion simultaneously; Promote probiotics growths such as bacillus bifidus; But balance intestinal microbial population also; Be beneficial to absorptions such as calcium, ferrum and can produce B group vitamin; Obviously shorten the intestinal emptying time; Helping the discharge of bile acid, is the excretory promoter of plumbous intestinal.
Used Plumbum absorption competitive inhibitor is a ferric lactate among the present invention, discover, under the situation of taking in equivalent lead, lead concentration in iron-deficient animals kidney and the skeletal tissue is high than the matched group of iron deficiency not, storage iron in the animal body is in case descend, even do not occur the performance of iron deficiency as yet, lead content has increased by six times in its tissue.The ferrum nutriture is poor more, and blood lead is high more.Relation between ferrum nutriture and the Toxicity of Lead effect is significant.The purpose of ferric lactate is to replenish ferrum element in the prescription, improves the anemia situation that lead poisoning and iron deficiency cause.
Plumbous metabolic antagonist is a zinc lactate among the present invention, discover, and zinc and the plumbous characteristic that mutual antagonism is arranged, the actuatable thing of zinc deficiency improves Toxicity of Lead effect sensitivity, and intestinal strengthens Plumbum absorption, and zinc supplement then blood lead concentration obviously reduces.Belong to nutrition enhancer simultaneously the growth of growth of children, intelligence, height, body weight is all had good effect.
Plumbous chelating agent is a vitamin C among the present invention, and research is thought, V
CMechanism of action relevant with the enediol group in its structure, can form the complexation ring with lead, and it is calm that lead is difficult in brain, nephridial tissue organ, simultaneously and V
CThe dissolubility of lead after the complexation in body fluid increases, and is convenient to excrete with urine plumbous accumulating in the ameliorate body.
Lead poisoning effect antagonist of the present invention is a calcium carbonate, studies show that, calcium is Plumbum absorption, accumulates and toxic antagonist, and calcium in the children mental retardation person hair, zinc content are than normal person's remarkable reduction, and lead content significantly increases.After replenishing calcium, can increase lead discharge capacity from urine, reduce plumbous accumulation in the bone.
Additive of the present invention can be various edible essences, fruit essence and sugar etc.The present invention can be tablet, electuary, capsule, oral liquid or other peroral dosage form.
For estimate this lead-expelling product safety, carried out mice LD
50, bone marrow micronucleus, sperm distortion and Salmonella reversion test, prove to the invention belongs to actual nontoxic level material that somatic cell is not had mutagenesis, sexual cell is not had the mutation teratogenesis, no direct or indirect mutagenic action.Referring to table 1-4.
Table 1 contains stachyose Pb excluding health care product The acute toxicity tests for one kind
| Dosage number of animals (only) animal dead number (g/kg) male and female male and female |
| ?5.0??????5?????5?????????0?????0 ?10.0?????5?????5?????????0?????0 ?15.0?????5?????5?????????0?????0 ?20.0?????5?????5?????????0?????0 |
Annotate: Horn ' s method; Animal: Wistar rat; Route of administration: irritate LD
50＞20.0g/kg.
Table 2 contains stachyose Pb excluding health care product mouse bone marrow cells micronucleus test for one kind
| Dosage number of animals (only) is subjected to inspection to have a liking for that polychromatophilia is red to have micronucleus PCE to lead PCE/NCE (g/kg) male and female cell number (individual) (‰) |
| 0.00 55 10,000 2.2 ± 1.03 1.22 ± 0.04 1.7 55 10,000 2.3 ± 1.76 1.20 ± 0.06 3.3 55 10,000 1.4 ± 0.76 1.23 ± 0.04 6.7 55 10,000 1.5 ± 0.53 .1.21 ± 0.05 ring mebenil 55 10,000 2.23 ± 7.15**?..1.18±0.08 ?24.9**(50mg/kg) |
Annotate: the positive group of several dosage groups of * * blank group and cyclophosphamide compares P＜0.01
Result: somatic cell is not had mutagenesis.
Table 3 influence that contains stachyose Pb excluding health care product mouse sperm deformity rate
| The dosage number of animals is examined the sperm count teratospermia and is counted abnormal rate (g/kg) (only) (bar) (bar) (‰) |
| Negative control group 5 5,000 82 1.68 ± 0.23 1.7 5 5,000 89 1.76 ± 0.52 3.3 5 5,000 96 1.89 ± 0.38 6.7 5 5,000 81 1.48 ± 0.37 endoxan 5 5,000 386 7.6 ± 0.789** |
Annotate: * * presses Wincoxon sequential test result, and blank and each dosage group and cyclophosphamide group compare, P＜0.01.
The result: a kind of when to contain stachyose Pb excluding health care product oral administration dosage be 6.7g/kg～1.7 g/kg body weight, do not find the effect of mutation sperm deformity yet.
Table 4 contains the dull and stereotyped infiltration method testing result (Salmonella reversion test) of stachyose Pb excluding health care product for one kind
| Tried thing TA97 TA98 TA100 TA102 ug/ ware-S9+S9-S9+S9-S9+S9-S9+S9 |
| Naturally return and become 177 36 193 302 0.5 152 167 30 31 156 173 293 312 5 144 171 28 29 170 182 272 329 50 147 162 32 33 160 163 289 314 500 162 157 27 32 162 167 316 317 5,000 168 172 23 29 159 167 270 306 positive control Dexon＞1000＞1000 Sodium azides＞1500 MMC＞1500 2-AF＞1000＞2000＞1,500 580 ± 10 |
Annotate: 1.TA97, TA102 do not add positive thing that S9 and TA102 add S9 with fenaminosulf 50ug/ ware.
2.TA97, TA98, TA100 add the positive useless 2-aminofluorene 5ug/ ware of S9.
3.TA100 do not add the positive thing of S9 sodium azide 1.5ug/ ware.
The result: no matter this prescription adds or does not add the S9 mixture, does not all find direct or indirect mutagenic action.
In sum, a kind of Pb excluding health care product that contains stachyose has its original feature, through the online information retrieval in pertinent literature storehouse both at home and abroad, does not see identical laboratory report, research report, fills a prescription and introduce and functional evaluation.Illustrate that this prescription has advance and practicality aspect treatment and the health care.
Concrete embodiment
Embodiment 1:
Stachyose Plumbum removing granule
Stachyose (by pure product) 1.5g
Zinc lactate 30mg
Ferrous lactate (three water things) 36mg
V
B1??????????????????10mg
V
C???????????????????50mg
CaCO
3????????????????1.0g
Correctives and right amount of auxiliary materials
Through batching, dry granulation, granulate, packing, finished product (4 gram/bag).
Embodiment 2: stachyose Plumbum removing capsule
Stachyose (by pure product) 2.0g
Zinc lactate 35mg
Ferrous lactate (three water things) 40mg
V
B1??????????????????8mg
V
C???????????????????48mg
CaCO
3????????????????8.0g
Correctives and right amount of auxiliary materials are through batching, granulation, dress capsule, packing, finished product.Embodiment 3: stachyose Plumbum removing tablet
Stachyose (by pure product) 1.8g
Zinc lactate 28mg
Ferrous lactate (three water things) 38mg
V
B1??????????????????10mg
V
C???????????????????50mg
CaCO
3????????????????1.0g
Correctives and right amount of auxiliary materials
Through mixing, granulation, tabletting, packing, finished product.
Embodiment 3: stachyose lead discharging oral liquid
Stachyose (by pure product) 1.8g
Zinc lactate 28mg
Ferrous lactate (three water things) 38mg
V
B1????????????????10mg
V
C?????????????????50mg
CaCO
3??????????????1.0g
Water 20ml
Correctives and right amount of auxiliary materials
Through dissolving, filtration, fill, sterilization, cooling, finished product.
Embodiment 4: stachyose Plumbum removing powder
Stachyose (by pure product) 2.0g
Zinc lactate 30mg
Ferrous lactate (three water things) 40mg
V
B1????????????????8mg
V
C?????????????????50mg
CaCO
3??????????????1.0g
Correctives and right amount of auxiliary materials
Mix homogeneously packing, finished product (4 gram/bag).
Claims (4)
1, a kind of Pb excluding health care product that contains stachyose is characterized in that each constituent content is as follows:
Stachyose (by pure product) 1.0g～3.0g
Zinc lactate 25g～35mg
Ferrous lactate (three water things) 35g～40mg
V
B1??????????????????8mg～12mg
V
C???????????????????48mg～50mg
CaCO
3????????????????0.5g～1.0g
Correctives and right amount of auxiliary materials.
2, a kind of Pb excluding health care product that contains stachyose according to claim 1 is characterized in that optimization formula is as follows:
Stachyose (by pure product) 1.0g～2.5g
Zinc lactate 30mg～35mg
Ferrous lactate (three water things) 36mg～40mg
V
B1?????????????????8mg～10mg，
V
C??????????????????45mg～50mg，
Caco
3???????????????0.8mg～1.0g，
Correctives and right amount of auxiliary materials
3, according to right 1 or 2 described a kind of Pb excluding health care products that contain stachyose, it is characterized in that containing new type functional oligosaccharide-stachyose (containing cottonseed sugar 8%～15%).
4, a kind of Pb excluding health care product that contains stachyose according to claim 1 and 2 is characterized in that this lead-expelling product can be granule, capsule, tablet, oral liquid and other dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021562075A CN100441198C (en) | 2002-12-10 | 2002-12-10 | Lead-removing health article containing stachyose |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021562075A CN100441198C (en) | 2002-12-10 | 2002-12-10 | Lead-removing health article containing stachyose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1506070A true CN1506070A (en) | 2004-06-23 |
| CN100441198C CN100441198C (en) | 2008-12-10 |
Family
ID=34236145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021562075A Expired - Fee Related CN100441198C (en) | 2002-12-10 | 2002-12-10 | Lead-removing health article containing stachyose |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100441198C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013127146A1 (en) | 2012-02-28 | 2013-09-06 | 江南大学 | Lactobacillus plantarum able to relieve lead toxicity and use thereof |
| CN107006863A (en) * | 2017-04-13 | 2017-08-04 | 广东太阳神集团有限公司 | It is a kind of to promote health food of lead discharging and preparation method thereof |
| CN108464508A (en) * | 2018-03-01 | 2018-08-31 | 递医（北京）科技有限公司 | A kind of composition and its preparation method and application for strengthening intestinal microecology |
| CN108497486A (en) * | 2018-03-16 | 2018-09-07 | 邓照曦 | A kind of lead discharging composition and lead discharging nutrition fortifier |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103349124A (en) * | 2013-07-22 | 2013-10-16 | 北京绿源求证科技发展有限责任公司 | Food type health tea electuary capable of promoting lead discharge |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0523183A (en) * | 1991-07-19 | 1993-02-02 | Nippon Shokuhin Kako Co Ltd | New alpha-galactosidase and production of sugar using the same |
-
2002
- 2002-12-10 CN CNB021562075A patent/CN100441198C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013127146A1 (en) | 2012-02-28 | 2013-09-06 | 江南大学 | Lactobacillus plantarum able to relieve lead toxicity and use thereof |
| CN107006863A (en) * | 2017-04-13 | 2017-08-04 | 广东太阳神集团有限公司 | It is a kind of to promote health food of lead discharging and preparation method thereof |
| CN108464508A (en) * | 2018-03-01 | 2018-08-31 | 递医（北京）科技有限公司 | A kind of composition and its preparation method and application for strengthening intestinal microecology |
| CN108497486A (en) * | 2018-03-16 | 2018-09-07 | 邓照曦 | A kind of lead discharging composition and lead discharging nutrition fortifier |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100441198C (en) | 2008-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1972676B (en) | Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens | |
| CN1283171C (en) | Selenium-rich probiotics foder additive production method and its product | |
| CN105029447A (en) | Sea-fish oligopeptide powder containing activated probiotics | |
| CN1506070A (en) | Lead-removing health article containing stachyose | |
| CN100464781C (en) | Nutrition liquid for chronic nephropathy and preparation method thereof | |
| CN101715907A (en) | Health care feed beneficial to pig and dog intestinal health and application thereof | |
| CN105454667A (en) | Feed additive capable of replacing antibiotics and preparation method of feed additive | |
| CN112704160A (en) | Feed for preventing sow constipation and preparation process thereof | |
| CN103892391A (en) | High-selenium-content germanium ganoderma ginseng detoxification and oxygenation fitness beverage | |
| Babkin | An Address on THE FACTORS REGULATING THE COMPOSITION OF THE GASTRIC JUICE | |
| CN1168498C (en) | Child 'xuebao' chewing tablet and preparing process thereof | |
| CN1117561C (en) | Compounded calcium preparation, preparing method and use thereof | |
| CN1187040C (en) | Anti-heatstroke effervescent beverage | |
| CN112753873A (en) | Low-protein Chinese herbal medicine type antibiotic-free fermented feed and preparation method and application thereof | |
| CN102335191A (en) | Preparation method of compound medicament for treating diarrhea | |
| CN101468029B (en) | Difructose anhydride-containing composition and use thereof | |
| CN1850270A (en) | Ovotransferrin iron supplement agent, and its preparing method and use | |
| CN1411738A (en) | Nuisance-free concentrated feed for animals and its production method | |
| CN1451395A (en) | Use of silkworm excrement extract for treating iron-deficiency anemia | |
| KR20110065873A (en) | Concentration liquid for cosmetics containing natural minerals and manufacturing method thereof | |
| CN1181076C (en) | Trace element-vitamine compound and its preparing process and application | |
| EP0634105A1 (en) | Calcium containing composition | |
| CN1408428A (en) | Sugar cane free poly peptide calcium compensation powder and its producing method | |
| CN1823817A (en) | Electrolyte nutrition fortification agent | |
| CN1210038C (en) | Application of N-acetylglucosamine in the preparation of medicine for treating viscera injure due to toxication from poison and medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081210 Termination date: 20101210 |